Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
Date
2016Author
Boussios, StergiosSeraj, E.
Zarkavelis, George
Petrakis, Dimitrios
Kollas, Aristomenes
Kafantari, Aikaterini
Assi, A.
Tatsi, K.
Pavlidis, Nicholas
Pentheroudakis, George
Source
Critical reviews in oncology/hematologyVolume
108Pages
164-174Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Background Cervical cancer is the fourth most common cancer affecting women worldwide. Despite advances in screening and human papillomavirus (HPV) vaccination, a significant number of women present with or develop advanced disease. Palliative platinum-based chemotherapy (CT) is the standard first-line treatment for metastatic/recurrent cervical cancer. The prognosis remains poor and effective second line options are urgently needed. Methods We searched the English-language medical literature as well as relevant guideline databases, published from January 1981 to December 2015 and identified publications related to cervical cancer and its therapies. Our effort was to highlight the available treatment options in the setting of recurrent/metastatic disease. Results Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease after platinum failure is still problematic. Overall, there is a trend in terms of longer overall survival (OS) and better quality of life for the combination of cisplatin/paclitaxel (PC) as compared to the doublets of cisplatin/topotecan (TC), cisplatin/vinorelbine (VC), and cisplatin/gemcitabine (GC). Currently available single agents beyond first-line platinum-based therapy have limited efficacy in this setting and include topoisomerase inhibitors, vinca alkaloids, taxanes, alkylating agents and antimetabolites. Several targeted therapies have demonstrated activity in advanced cervical cancer. Bevacizumab has been evaluated in a phase III trial using doublets of cisplatin with paclitaxel or topotecan and has been approved in the first-line setting by the U. S. Food and Drug Administration. Selective targeting of angiogenic kinases by tyrosine kinase inhibitors (TKIs) may represent a novel therapeutic tool in this setting, but its use alone or in combination with CT is still investigational. Early reports have implicated PI3KCA somatic mutations suggesting that mTOR-targeted agents should be explored in this disease. Development of the immune checkpoint programmed cell death 1 (PD-1) and T-lymphocyte–associated molecule-4 (CTLA-4) inhibitors have been of considerable interest, leading to ongoing phase II studies in patients with advanced cervical cancer. Conclusions Progress in the management of recurrent and advanced cervical cancer patients has been slow and restricted to palliative intent. These patients should be considered for clinical trials of novel targeted agents and/or immunotherapy. © 2016 Elsevier Ireland Ltd
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
«Juvenile» oncology - A missing subspecialty. The experience of a reference cancer centre
Pentheroudakis, George; Mauri, D.; Kostadima, Lida; Golfinopoulos, Vassilis; Alexiou, G.; Karakatsanis, A.; Pavlidis, Nicholas (2006)Introduction: Despite unique tumor epidemiology and a higher cancer incidence compared to pediatric patients, adolescents and young adults have not been receiving specialized, multidisciplinary, centralized care. In an ...
-
Article
Cancer of unknown primary site
Pavlidis, Nicholas; Pentheroudakis, George (2012)Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...
-
Article
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)